Back to Ticker
Tatva Chintan Pharma Chem Limited
NSE: TATVA₹1,903.4
-2.09%EOD · 19 OctMarket Cap
₹4,452 Cr
52W Range
₹2009 / ₹1044
Volume
143K
38.0% delivery
1Y Return
+78.0%
P/E Ratio
88.5
P/B Ratio
5.8
ROE
5.5%
Debt / Equity
15.40
Quality Score
Durability · Valuation · Momentum — objective math, not adviceC
50/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityWeak · 35
ValuationPoor · 20
MomentumStrong · 100
High debt load (D/E 15.4)
In confirmed uptrend (Stage 2)
Very expensive valuation (P/E 88x)
Technical Indicators
Full analysis · objective math, not adviceReturns
1D
-2.1%
1W
+1.7%
1M
+11.3%
3M
+11.1%
6M
+48.9%
1Y
+78.0%
Weinstein Stage
Stage 2 — Advancing (uptrend) RSI (14)
59 Neutral
Trend Template
7/7strong
RS vs Nifty (3M)
+17.5pp
Moving Averages (price vs MA)
20-DMA
₹1833
above
50-DMA
₹1730
above
150-DMA
₹1441
above
200-DMA
₹1390
above
From 52W High
-5.2%
From 52W Low
+82.3%
Support (20D)
₹1683
Resistance (20D)
₹2009
Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.
News & FilingsGoogle News + BSE
Tatva Chintan (NSE:TATVA) Q2FY27 Earnings Call Date
Kalkine India· 6d agoTatva Chintan Pharma Chem Share Price Target 2027 to 2030
Univest· 18 AugTATVA Stock Price and Chart — NSE:TATVA
TradingView· 14 DecTatva Chintan Pharma Chem Limited (NSE:TATVA) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
Simply Wall Street· 22 JulMukul Agrawal portfolio stock Tatva Chintan Pharma zooms 20%; here's why
Business Standard· 20 JulVolume Gainers | July 20, 2026
HDFC Sky· 20 Jul
News via Google News · Not verified by IPOpulse · Not investment advice
Community discussion(0)
Sign in to join the discussion.
Sign inNo comments yet — be the first to share your view.